Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 11 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5 AND LACTATED RINGER S IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 11 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5 AND LACTATED RINGER S IN PLASTIC CONTAINER.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the major intracellular cation, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides caloric supplementation.
Potassium chloride provides potassium ions for maintenance of electrolyte balance and repolarization of cell membranes. Dextrose 5% provides caloric supplementation and may enhance potassium uptake into cells via insulin-mediated mechanisms. Lactated Ringer's solution provides isotonic crystalloid fluid, electrolytes (sodium, calcium, lactate), and buffer (bicarbonate precursor) to maintain intravascular volume and acid-base balance.
Intravenous infusion at a rate not exceeding 10 mEq/h (using 0.11% potassium chloride in 5% dextrose), typically 10-20 mEq over 4-6 hours for mild hypokalemia, with a maximum concentration of 40 mEq/L via peripheral line.
Intravenous infusion: 10–20 mEq/hour, not to exceed 20–40 mEq in 4 hours or 150 mEq per 24 hours. Rate: max 10 mEq/hour (1 mEq/mL concentration).
None Documented
None Documented
Potassium has no true elimination half-life as it is homeostatically regulated; the terminal half-life of a potassium load is approximately 8-12 hours in healthy individuals, but this is highly variable and dependent on renal function, aldosterone status, and body stores. In anuric patients, potassium clearance is minimal, and dangerous accumulation can occur within hours.
Potassium does not have a classical elimination half-life as it is an electrolyte with complex distribution and regulation. After a single IV dose, plasma levels decline rapidly due to redistribution, with an initial distribution half-life of about 1 hour. The terminal phase reflects slow equilibration with total body stores and is influenced by renal function; in anephric patients, the effective half-life is extended significantly.
Primarily renal; >90% of potassium is excreted by the kidneys, with approximately 10% lost in feces. In steady state, urinary potassium excretion matches dietary intake (typically 40-120 mEq/day). Dextrose is completely metabolized; unchanged dextrose excretion is negligible (<1% renal) in normoglycemic individuals.
Potassium is primarily excreted renally (90%) via glomerular filtration and active secretion in the distal tubule; approximately 10% is lost in feces. In patients with normal renal function, urinary excretion is increased when intake is high. In the presence of renal impairment, elimination is decreased, leading to hyperkalemia risk. Dialysis (hemodialysis or peritoneal dialysis) can remove potassium.
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement